Biocon launches BioWISE program to empower women in STEM across Karnataka

By Aditya Bhagchandani Published on June 9, 2025, 17:01 IST
Biocon Foundation, the CSR arm of Biocon Group, has announced the launch of its new BioWISE (Women in STEM Empowered) program in partnership with the National Centre for Biological Sciences (NCBS) and the Bengaluru Science and Technology (BeST) Cluster. The initiative aims to support 25 women science students from tier 2 and 3 universities across Karnataka to build careers in life sciences through internships, mentorships, and training.
This first-of-its-kind program will support 15 postgraduate and 10 undergraduate students from underserved communities, offering six-month and three-month mentorship and hands-on exposure respectively. The initiative is structured to include lab visits, bio-incubation centre tours, soft skills training, and continuous mentor-mentee sessions with experts from Biocon Biologics, NCBS, and other partner institutions.
Chairperson Dr. Kiran Mazumdar-Shaw emphasized that empowering women in STEM is a strategic investment in India's future. The program will be hosted at NCBS, while BeST Cluster will oversee design and implementation. Biocon Biologics will also provide professional mentorship.
The launch event witnessed participation from various dignitaries and scientists, with all stakeholders committing to building an inclusive scientific ecosystem that ensures equitable access to research, education, and opportunity.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

a day ago

• Business Upturn

Patanjali Foods receives FSSAI prohibition order on Ruchi No 1 Vanaspati batch

By Aditya Bhagchandani Published on June 21, 2025, 17:36 IST Patanjali Foods Ltd. has disclosed a regulatory development involving one of its products, Ruchi No 1 Vanaspati. The company received an official email communication on June 20, 2025, from the Assistant Director of the FSSAI's Central Licensing Authority in Kolkata. The notice prohibits the sale of a specific batch—HAE03702A—of Ruchi No 1 Vanaspati, citing non-conformity with a prescribed norm under Section 3(1)(zz)(xii) of the Food Safety & Standards Act, 2006. The company clarified that the issue pertains only to this batch and emphasized that the total financial implication is limited to approximately Rs 2.27 lakh. Patanjali Foods stated that there will be no material impact on the company's financial or operational performance due to this order. As a response, the company is pursuing appropriate legal action and has initiated an appeal against the order. No penalties, other than the prohibition of sale for the identified batch, have been imposed so far. This update was shared with the stock exchanges under Regulation 30 of SEBI Listing Regulations. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Business Upturn

2 days ago

• Business Upturn

Aarvi Encon secures twin manpower contracts worth over Rs 30 crore

By Aditya Bhagchandani Published on June 20, 2025, 16:40 IST Aarvi Encon Limited has announced the receipt of two significant work orders from a leading multinational EPC company, with a combined value exceeding Rs 30.67 crore. As per the company's regulatory filings, the first contract is worth Rs 22.53 crore and entails supplying manpower on an outsourcing basis to various project sites and offices across India. This contract is valid for two years starting June 3, 2025, and will continue until June 4, 2027. In addition to this, Aarvi Encon has secured a second contract valued at Rs 8.13 crore. This one-year agreement, effective from July 1, 2025, involves similar manpower supply services at multiple domestic locations. Both contracts are with the same unnamed domestic entity and fall under non-related party transactions. The company has signed a Non-Disclosure Agreement, and therefore, the client's identity remains confidential. These orders bolster Aarvi Encon's pipeline and reaffirm its positioning in India's engineering staffing and outsourcing segment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Business Upturn

2 days ago

• Business Upturn

Granules India's Bonthapally facility completes US FDA inspection with one observation

By Aditya Bhagchandani Published on June 20, 2025, 16:28 IST Granules India announced on June 20, 2025, that its API Unit-I facility at Bonthapally, located in Sangareddy District near Hyderabad, has successfully completed a US FDA inspection conducted between June 16 and June 20. The inspection concluded with a single Form 483 observation. In an exchange filing, the company stated it would address the observation within the prescribed timeline. Granules emphasized that the Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing units by volume and also houses manufacturing plants for Metformin and Guaifenesin APIs. The company assured investors that the outcome will be managed in line with regulatory expectations. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.